Company Filing History:
Years Active: 2019-2022
Title: Miia Lehtinen: Innovator in Cardiac Research
Introduction
Miia Lehtinen is a prominent inventor based in Tuusula, Finland. She has made significant contributions to the field of cardiac research, particularly in the isolation of human cardiac ventricular progenitor cells. With a total of 2 patents to her name, her work is paving the way for advancements in cardiac repair and toxicity screening.
Latest Patents
Lehtinen's latest patents focus on innovative methods for isolating human cardiac ventricular progenitor cells (HVPs). These methods involve the negative selection of cultures of day 5-7 cardiac progenitor cells for specific markers expressed on human pluripotent stem cells, such as TRA-1-60. Additionally, her patents include positive selection for a second marker from a defined group, which enhances the isolation process. The patents also detail the in vivo applications of HVPs for cardiac repair and improving cardiac function, as well as their use in cardiac toxicity screening of test compounds.
Career Highlights
Miia Lehtinen is currently associated with Procella Therapeutics Ab, where she continues her groundbreaking research. Her work has garnered attention in the scientific community, contributing to the understanding of cardiac progenitor cells and their potential applications in regenerative medicine.
Collaborations
Lehtinen collaborates with notable professionals in her field, including Kenneth R. Chien and Jonathan Clarke. These partnerships enhance her research efforts and contribute to the advancement of cardiac therapies.
Conclusion
Miia Lehtinen's innovative work in isolating cardiac progenitor cells represents a significant advancement in cardiac research. Her contributions are vital for future developments in cardiac repair and toxicity screening, showcasing her role as a leading inventor in this important field.